GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (NZSE:TRU) » Definitions » YoY EBITDA Growth

Truscreen Group (NZSE:TRU) YoY EBITDA Growth : 50.00% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Truscreen Group YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Truscreen Group's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 50.00%.

Truscreen Group's EBITDA per Share for the six months ended in Sep. 2024 was NZ$-0.00.


Truscreen Group YoY EBITDA Growth Historical Data

The historical data trend for Truscreen Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Truscreen Group YoY EBITDA Growth Chart

Truscreen Group Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.15 57.89 -175.00 63.64 25.00

Truscreen Group Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 77.78 - 50.00 50.00

Truscreen Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Truscreen Group's YoY EBITDA Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (A: Mar. 2024 )
=(EBITDA per Share (A: Mar. 2024 )-EBITDA per Share (A: Mar. 2023 ))/ | EBITDA per Share (A: Mar. 2023 ) |
=(-0.006--0.008)/ | -0.008 |
=25.00 %

Truscreen Group's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(-0.002--0.004)/ | -0.004 |
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Truscreen Group YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Truscreen Group's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Truscreen Group Business Description

Traded in Other Exchanges
Address
C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.